Biotech

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?

Biotech Recent News

Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia.
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in sales.
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
FDA approves ImmunityBio's Anktiva plus Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer. Anktiva shows promising complete response rates and duration exceeding 24 months.
FDA Rejects Approval Of Abeona Therapeutics' Skin Disorder Treatment, Shares Sink
Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Manufacturing and Controls requirements.
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.
Ohio Hemp Company Re-Greening The Rust Belt With Bioplastics Option For Midwest Auto Industry
The Ohio Hemp Company has formalized a partnership with Heartland Industries, based in Michigan, to cultivate hemp fiber destined for the burgeoning bioplastics market.
Beyond Amazon And Coca-Cola: Why Cannabis Is Catching Up To Blue Chip Stocks In Profitability
A recent report by Viridian Capital Advisors explores the valuation and growth prospects of cannabis stocks against those of well-established sectors like alco
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."
Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?
Phio Pharmaceuticals unveils findings on PH-762, a promising candidate for cancer therapy. Discover its rapid cell uptake and tumor-inhibiting potential.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers